FDA makes CBER and CDER leaders permanent amid pending commissioner confirmation

The FDA announced that the heads of its two major centers, CBER and CDER, have been given permanent appointments.

The move provides stability for the centers that oversee biologics and drugs, respectively, while the agency awaits confirmation of a new commissioner.

The decision was communicated by HHS on Tuesday and follows recent discussions between the leaders and industry groups.

Analysts view the appointments as a sign of continuity, but no policy changes were indicated.